Astellas Pharma and Pfizer said FDA has approved a supplemental New Drug Application for Xtandi (enzalutamide), following FDA Priority Review designation, based on results from the phase III PROSPER trial.
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
